Pagoclone

This classification denotes an anxiolytic with the molecular formula C23H22ClN3O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 38VAG2SA33, chemically known as 2-(7-chloro-2-naphthyridin-1,8-yl)-3-(5-methyl-2-oxohexyl)isoindolin-1-one but generally known as pagoclone, which bears US NIH Compound Identifier 131664. European Medicines Agency schedules Pagoclone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09586MIG. The term PAGOCLONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 10, No. 3, 1996, List 36). PAGOCLONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule pagoclone under HS 29337900 and SITC 51561. As of Q4 2014, PAGOCLONE remains the US FDA Preferred Term for this commodity. Pagoclone bears US NLM identifiers UMLS ID C1120452 and NCI Concept Code C74529. SMILES: CLC1NC2NC(N3C(CC(=O)CCC(C)C)C4C(C3=O)CCCC4)CCC2CC1.